Blueprint Medicines Corporation (NASDAQ:BPMC) insider Anthony L. Boral sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $70.40, for a total value of $352,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Blueprint Medicines Corporation (BPMC) opened at $68.32 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.28 and a quick ratio of 11.28. Blueprint Medicines Corporation has a 52 week low of $25.08 and a 52 week high of $74.42.
Blueprint Medicines Corporation (NASDAQ:BPMC) last released its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.06). Blueprint Medicines Corporation had a negative return on equity of 43.11% and a negative net margin of 437.83%. The firm had revenue of $8.07 million for the quarter, compared to analyst estimates of $5.35 million. During the same quarter last year, the company earned ($0.62) earnings per share. The firm’s revenue for the quarter was up 31.0% on a year-over-year basis. sell-side analysts predict that Blueprint Medicines Corporation will post -3.74 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the business. Rockefeller Financial Services Inc. purchased a new stake in shares of Blueprint Medicines Corporation during the third quarter worth $160,000. Ameritas Investment Partners Inc. increased its position in shares of Blueprint Medicines Corporation by 68.9% during the second quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 1,391 shares during the period. UBS Asset Management Americas Inc. purchased a new stake in shares of Blueprint Medicines Corporation during the first quarter worth $201,000. Fred Alger Management Inc. purchased a new stake in shares of Blueprint Medicines Corporation during the second quarter worth $203,000. Finally, SG Americas Securities LLC increased its position in shares of Blueprint Medicines Corporation by 23.3% during the second quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock worth $208,000 after acquiring an additional 778 shares during the period. Institutional investors own 90.79% of the company’s stock.
BPMC has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Blueprint Medicines Corporation from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Canaccord Genuity set a $56.00 price objective on Blueprint Medicines Corporation and gave the company a “buy” rating in a report on Wednesday, August 2nd. BidaskClub cut Blueprint Medicines Corporation from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 19th. Wedbush reiterated an “outperform” rating and issued a $66.00 price objective on shares of Blueprint Medicines Corporation in a report on Tuesday, August 22nd. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $56.00 price objective on shares of Blueprint Medicines Corporation in a report on Tuesday, September 5th. One analyst has rated the stock with a sell rating and ten have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $70.47.
Blueprint Medicines Corporation Company Profile
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.